T. Rowe Price Investment Management, Inc. - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.

Quarter-by-quarter ownership
T. Rowe Price Investment Management, Inc. ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$165,757
-19.0%
3,651,833
+0.1%
0.12%
-15.8%
Q2 2023$204,720
+23.5%
3,646,582
-0.5%
0.14%
+16.8%
Q1 2023$165,740
+36.2%
3,664,371
+22.4%
0.12%
+28.0%
Q4 2022$121,689
-99.9%
2,993,577
+33.6%
0.09%
-20.5%
Q3 2022$146,479,0002,241,4450.12%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 508,558$82,330,00027.28%
Valiant Capital Management, L.P. 307,700$49,814,0003.74%
NEA Management Company, LLC 1,590,002$257,405,0003.35%
NIA IMPACT ADVISORS, LLC 39,891$6,458,0003.15%
Ikarian Capital, LLC 200,000$32,379,0002.62%
Soleus Capital Management, L.P. 103,114$16,693,0002.57%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 157,334$25,471,0002.47%
Capital Impact Advisors, LLC 45,440$7,356,0002.37%
ARK Investment Management 7,776,119$1,258,876,0002.34%
Sassicaia Capital Advisers LLC 13,513$2,188,0002.28%
View complete list of CRISPR THERAPEUTICS AG shareholders